The Implications of WTO Accession on the Pharmaceutical Industry in China
Bibliographic Data
| ID | 12422601 |
|---|---|
| Authors | Godfrey Yeung (0000-0002-7027-5005, corresponding author) |
| Year | 2002 |
| Volume | 11 |
| Issue | 32 |
| Pages | 473-493 |
| Publication date | 2002-08-01 |
| Peer Reviewed | Yes |
| Open Access | No |
| Type | ARTICLE |
| Venue | Journal of Contemporary China (JOURNAL) |
| Journal identifiers | ISSN: 1067-0564 • E-ISSN: 1469-9400 |
| Publisher | Routledge (PUBLISHER • GB) |
| DOI | 10.1080/10670560220152292 |
| OpenAlex | W2116226564 |
| Language | EN |
| Citations received | 2 |
| References cited | 6 |
Given the limited capabilities of R&D and global distribution channels, and the virtual non-existence of patented drugs, the Chinese pharmaceutical industry has little chance to enter the global market of Western prescription drugs and compete with the established global giants head-on. The reality is that they are chasing a moving target and their competitors are becoming bigger and stronger day by day. The substantial reduction of import tariffs and the granting of comprehensive trading and distribution rights to foreign-financed firms following WTO accession, effectively tilted the level-playing field against the Chinese pharmaceutical industry. Given the short-term competitive advantages of the Chinese pharmaceutical industry on Chinese drugs, three development strategies are suggested: (1) consolidate the local market of herbal and generic drugs; (2) market Chinese drugs via the Internet; and (3) outsource R&D and collaborative marketing
Accession · Biology · Business · China · International trade · Pharmaceutical industry · Political science · Biotechnology and Related Fields · Innovation and Knowledge Management · International Business and FDI · Law · Biotechnology
| Unique citing works | 2 |
|---|---|
| Citations per year | 0,1 |
| Citation span | 2006 - 2018 (13) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 2 |